32P - Clinicopathologic features and prognostic factors in male breast cancer: A single centre experience

Background

To evaluate clinicopathologic features and prognostic factors in male breast cancer (MBC).

Methods

The data of 80 patients were retrospectively reviewed. The clinicopathological features, receptor status (ER, PR, and Her2), BRCA mutation status, tumor stage, and treatment data were recorded. Kaplan-Meier method and Cox regression analysis were used for overall survival (OS) analysis.

Results

The median follow-up period was 47 months (range: 2.2-214.6 months). The median age at diagnosis was 61 years (range: 25-86 years). BRCA mutations were detected in 31% of the patients. The most common histological type of tumor was invasive ductal carcinoma (84%). The ratios of estrogen and progesterone receptor positivity were 93.6% and 74.4%, respectively. Her2 overexpression was present in 16.9%. Locoregional recurrence and distant metastases were observed in 1 (1.4%), and 21 (28.4%) patients, respectively. The median OS was 120.9 ± 25.8 months (70.3-171.5 months). The five years OS was 74.9 ± 6%. BRCA mutation status did not affect OS in univariate analysis (p=0.501). Smoking (p=0.037) and CA15-3 levels (p=0.033) at diagnosis were significantly associated with OS in univariate analysis, however, it was not confirmed by multivariate analysis.

Conclusions

In this study, we showed to BRCA mutations, smoking, regular alcohol consumption, body mass index (BMI), and family history of breast cancer were not affect on the OS.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.